New Jersey-based Acrotech Biopharma, a wholly-owned subsidiary of Aurobindo Pharma USA Inc., entered into a licensing agreement with Evive Biotech a subsidiary of China's Yifan Pharmaceutical Company Ltd., to commercialize Ryzneuta in the U.S. market. The product, a novel dimeric G-CSF long-acting fusion protein without pegylation, is presently under late-stage...